Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis

Tuberculosis

Volumn 94, Issue 3, 2014, Pages 187-196

  Nahid, Payam ^a   Bliven Sizemore, Erin ^b   Jarlsberg, Leah G ^a   De Groote, Mary A ^c,d   Johnson, John L ^e   Muzanyi, Grace ^e   Engle, Melissa ^f   Weiner, Marc ^f   Janjic, Nebojsa ^d   Sterling, David G ^d   Ochsner, Urs A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d SomaLogic Inc   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Biomarkers; Logistic regression model; Multiplex analysis; Proteomics; SOMAscan; Treatment response; Tuberculosis

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; ALPHA 2 ANTIPLASMIN; AMINOPEPTIDASE; APTAMER; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; CATZ PROTEIN; CDON PROTEIN; CNDP1 PROTEIN; EPHRIN RECEPTOR A1; EXTRACELLULAR MATRIX PROTEIN 1; GALECTIN 8; GLYCOPROTEIN GP 130; HEAT SHOCK PROTEIN 70; INTERLEUKIN 11 RECEPTOR ALPHA; INTERLEUKIN 7; MATRIX PROTEOGLYCAN; MRC2 PROTEIN; NECTIN LIKE PROTEIN 2; PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1; PROTEIN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; PROTEOGLYCAN; SERUM AMYLOID A; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XAA PRO AMINOPEPTIDASE 1; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UGANDA; BLOOD; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG COMBINATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTEOMICS; SELEX APTAMER TECHNIQUE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84900823547     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.01.006     Document Type: Article

References (48)

1. A. Zumla, P. Nahid, and S.T. Cole Advances in the development of new tuberculosis drugs and treatment regimens Nat Rev Drug Discov 12 2013 388 404
2. L.E. Dodd, and M.A. Proschan Innovative trial designs to improving tuberculosis drug development J Infect Dis 207 2013 544
3. A.M. Ginsberg Tuberculosis drug development: progress, challenges, and the road ahead Tuberculosis (Edinb) 90 2010 162 167
4. C. Lienhardt, A. Vernon, and M.C. Raviglione New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Curr Opin Pulm Med 16 2010 186 193
5. M. Spigelman, R. Woosley, and J. Gheuens New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades Int J Tuberc Lung Dis 14 2010 663 664
6. R.S. Wallis Sustainable tuberculosis drug development Clin Infect Dis 56 2013 106 113
7. W.J. Burman The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment Am J Respir Crit Care Med 167 2003 1299 1301
8. A. Chakera, A. Lucas, and M. Lucas Surrogate markers of infection: interrogation of the immune system Biomark Med 5 2011 131 148
9. P. Nahid, J. Saukkonen, and W.R. Mac Kenzie et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap Am J Respir Crit Care Med 184 2011 972 979
10. J. Nemeth, H.M. Winkler, and L. Boeck et al. Specific cytokine patterns of pulmonary tuberculosis in Central Africa Clin Immunol 138 2011 50 59
11. R.S. Wallis Surrogate markers to assess new therapies for drug-resistant tuberculosis Expert Rev Anti Infect Ther 5 2007 163 168
12. R.S. Wallis, T.M. Doherty, and P. Onyebujoh et al. Biomarkers for tuberculosis disease activity, cure, and relapse Lancet Infect Dis 9 2009 162 172
13. R.S. Wallis, P. Kim, and S. Cole et al. Tuberculosis biomarkers discovery: developments, needs, and challenges Lancet Infect Dis 13 2013 362 372
14. P.S. Kim, M. Makhene, C. Sizemore, and R. Hafner Viewpoint: challenges and opportunities in tuberculosis research J Infect Dis 205 2012 S347 S352
15. M.A. DeGroote, P. Nahid, and L. Jarlsberg et al. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment Plos One 8 2013 e61002 10.1371/journal.pone.0061002
16. J.D. Vaught, C. Bock, and J. Carter et al. Expanding the chemistry of DNA for in vitro selection J Am Chem Soc 132 2010 4141 4151
17. L. Gold, D. Ayers, and J. Bertino et al. Aptamer-based multiplexed proteomic technology for biomarker discovery PLoS One 5 2010 e15004
18. S. Kraemer, J.D. Vaught, and C. Bock et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay PLoS One 6 2011 e26332
19. M.R. Mehan, R. Ostroff, and S.K. Wilcox et al. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics Adv Exp Med Biol 734 2013 283 300
20. S.E. Dorman, S. Goldberg, and J.E. Stout et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium J Infect Dis 206 2012 1030 1040
21. L. Gold, J.J. Walker, S.K. Wilcox, and S. Williams Advances in human proteomics at high scale with the SOMAscan proteomics platform N Biotechnol 29 2012 543 549
22. R. Ostroff, T. Foreman, T.R. Keeney, S. Stratford, J.J. Walker, and D. Zichi The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array J Proteomics 73 2010 649 666
23. M. Hollander, and D.A. Wolfe Nonparametric statistical methods 2nd ed. 1999 John Wiley
24. G.A.F. Seber, and A.J. Lee Linear regression analysis 2nd ed. 2003 John Wiley
25. J.D. Storey A direct approach to false discovery rates J R Stat Soc Ser B 64 2002 479 498
26. A. Dabney, J.D. Storey, and G.R. Warnes qvalue: Q-value estimation for false discovery rate control 2011 R package version 1.26.0 http://CRAN.R- project.org/package=qvalue
27. N. Meinshausen, and P. Buhlmann High-dimensional graphs and variable selection with the lasso Ann Statistics 34 2006 1436 1462
28. K. Kohda, T. Ishibashi, N. Shimbara, K. Tanaka, Y. Matsuda, and M. Kasahara Characterization of the mouse PA28 activator complex gene family: complete organizations of the three member genes and a physical map of the approximately 150-kb region containing the alpha- and beta-subunit genes J Immunol 160 1998 4923 4935
29. Y.C. Yang, and T. Yin Interleukin-11 and its receptor Biofactors 4 1992 15 21
30. Y.S. Jang, J.H. Kim, G.Y. Seo, and P.H. Kim TGF-beta1 stimulates mouse macrophages to express APRIL through Smad and p38MAPK/CREB pathways Mol Cells 32 2011 251 255
31. S. Ebert, R. Nau, and U. Michel Role of activin in bacterial infections: a potential target for immunointervention? Immunotherapy 2 2010 673 684
32. S.S. Allen, L. Cassone, T.M. Lasco, and D.N. McMurray Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs Infect Immun 72 2004 1358 1363
33. Y. Sakai, K. Uchida, and H. Nakayama Histopathological features and expression profiles of cytokines, chemokines and SOCS family proteins in trehalose 6,6'-dimycolate-induced granulomatous lesions Inflamm Res 60 2011 371 378
34. G. Yu, T. Boone, and J. Delaney et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity Nat Immunol 1 2000 252 256
35. P.T. Elkington, C.A. Ugarte-Gil, and J.S. Friedland Matrix metalloproteinases in tuberculosis Eur Respir J 38 2011 456 464
36. P. LaPan, J. Brady, and C. Grierson et al. Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum BMC Pulm Med 10 2010 40
37. S. Wadhwa, M.C. Embree, Y. Bi, and M.F. Young Regulation, regulatory activities, and function of biglycan Crit Rev Eukaryot Gene Expr 14 2004 301 315
38. P.J. Cardona A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis Clin Dev Immunol 2011 2011 868246
39. M.G. Smit van Dixhoorn, R. Munir, and G. Sussman et al. Gene expression profiling of suppressor mechanisms in tuberculosis Mol Immunol 45 2008 1573 1586
40. S. Weijer, C.W. Wieland, S. Florquin, and T. van der Poll A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis Blood 106 2005 2761 2768
41. A.C. Hesseling, G. Walzl, and D.A. Enarson et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients Int J Tuberc Lung Dis 14 2010 560 570
42. T.H. Holtz, M. Sternberg, and S. Kammerer et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome Ann Intern Med 144 2006 650 659
43. F. Sahin, and P. Yildiz Serum CA-125: biomarker of pulmonary tuberculosis activity and evaluation of response to treatment Clin Invest Med 35 2012 E223 E228
44. W.C. Huang, C.W. Tseng, K.M. Chang, J.Y. Hsu, J.H. Chen, and G.H. Shen Usefulness of tumor marker CA-125 serum levels for the follow-up of therapeutic responses in tuberculosis patients with and without serositis Jpn J Infect Dis 64 2011 367 372
45. D. Agranoff, D. Fernandez-Reyes, and M.C. Papadopoulos et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum Lancet 368 2006 1012 1021
46. S.H. Gillespie, and N. Kennedy Weight as a surrogate marker of treatment response in tuberculosis Int J Tuberc Lung Dis 2 1998 522 523
47. L.E. Desjardin, M.D. Perkins, and K. Wolski et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy Am J Respir Crit Care Med 160 1999 203 210
48. F.M. Perrin, M.C. Lipman, T.D. McHugh, and S.H. Gillespie Biomarkers of treatment response in clinical trials of novel antituberculosis agents Lancet Infect Dis 7 2007 481 490